189 related articles for article (PubMed ID: 27161973)
1. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study.
Kawaguchi T; Koh Y; Ando M; Ito N; Takeo S; Adachi H; Tagawa T; Kakegawa S; Yamashita M; Kataoka K; Ichinose Y; Takeuchi Y; Serizawa M; Tamiya A; Shimizu S; Yoshimoto N; Kubo A; Isa S; Saka H; Matsumura A
J Clin Oncol; 2016 Jul; 34(19):2247-57. PubMed ID: 27161973
[TBL] [Abstract][Full Text] [Related]
2. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
Chapman AM; Sun KY; Ruestow P; Cowan DM; Madl AK
Lung Cancer; 2016 Dec; 102():122-134. PubMed ID: 27987580
[TBL] [Abstract][Full Text] [Related]
4. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
5. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
6. Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.
Soo RA; Kubo A; Ando M; Kawaguchi T; Ahn MJ; Ou SI
Clin Lung Cancer; 2017 Sep; 18(5):535-542. PubMed ID: 28433570
[TBL] [Abstract][Full Text] [Related]
7. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
[TBL] [Abstract][Full Text] [Related]
8. Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan.
Ogawa K; Koh Y; Kaneda H; Izumi M; Matsumoto Y; Sawa K; Fukui M; Taniguchi Y; Yoshimoto N; Tamiya A; Ando M; Kubo A; Isa SI; Saka H; Matsumura A; Kawaguchi T
BMJ Open; 2020 Sep; 10(9):e035615. PubMed ID: 32907893
[TBL] [Abstract][Full Text] [Related]
9. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
10. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
Lee SM; Bae SK; Jung SJ; Kim CK
Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
[TBL] [Abstract][Full Text] [Related]
11. Proportion and clinical features of never-smokers with non-small cell lung cancer.
Cho J; Choi SM; Lee J; Lee CH; Lee SM; Kim DW; Yim JJ; Kim YT; Yoo CG; Kim YW; Han SK; Park YS
Chin J Cancer; 2017 Feb; 36(1):20. PubMed ID: 28179026
[TBL] [Abstract][Full Text] [Related]
12. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
Zhang W; Stabile LP; Keohavong P; Romkes M; Grandis JR; Traynor AM; Siegfried JM
J Thorac Oncol; 2006 Sep; 1(7):635-47. PubMed ID: 17409930
[TBL] [Abstract][Full Text] [Related]
13. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
[TBL] [Abstract][Full Text] [Related]
14. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
[TBL] [Abstract][Full Text] [Related]
16. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
17. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
[TBL] [Abstract][Full Text] [Related]
18. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
[TBL] [Abstract][Full Text] [Related]
19. [EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance].
Zhao J; Gao J; Guo L; Hu X; Liu Q; Zhao J; Liu L; Jiang J; Wang M; Liang Z; Xu Y; Chen M; Zhang L; Li L; Zhong W
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):617-622. PubMed ID: 28935015
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
Lee B; Lee T; Lee SH; Choi YL; Han J
Oncotarget; 2016 Apr; 7(17):23874-84. PubMed ID: 26992209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]